Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Himanshu Suri

Pain Medicine Hallandale Beach, FL Medical Doctor

NPI 1073977328 CMS profile 5702564

2500 E Hallandale Beach Blvd Ste 211, Hallandale Beach, FL 33009

Open in the dashboard

General payments

$25,486

125 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Himanshu Suri of Hallandale Beach, FL is reported in the CMS Open Payments database as having received $25,486 across 125 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,924 35
2023 General $906 41
2022 General $944 15
2021 General $21,452 26
2020 General $206 5
2019 General $54 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Himanshu Suri
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Himanshu Suri were reported at $1,924. Among 95 Pain Medicine profiles paid that year, the median was $405 and the middle half received between $116 and $1,740.

Show as a table
Year Himanshu Suri Pain Medicine median Middle half National median
2019 $54 $298 $103–$1,153 $163
2020 $206 $188 $57–$916 $114
2021 $21,452 $365 $109–$1,150 $132
2022 $944 $498 $104–$1,575 $149
2023 $906 $334 $108–$1,267 $160
2024 $0 $544 $144–$1,302 $164
2025 $1,924 $405 $116–$1,740 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $12,162 28 payments
  2. Medtronic, Inc. $10,332 5 payments
  3. Nalu Medical, Inc. $783 19 payments
  4. Nevro Corp. $384 6 payments
  5. Scilex Pharmaceuticals Inc. $347 19 payments
  6. SPR Therapeutics, Inc $222 2 payments
  7. Abbott Laboratories $220 3 payments
  8. Merz North America, Inc. $133 1 payment
  9. Allergan Inc. $131 7 payments
  10. Forte Bio-Pharma LLC $122 7 payments
  11. Other $651 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $20,000 2 payments
  2. Food and Beverage $5,439 120 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $47 3 payments
Products named General payments · program years 2019–2025
  1. WAVEWRITER ALPHA $10,161 2 payments
  2. SYNCHROMED $10,000 1 payment
  3. Nalu Neurostimulation System $783 19 payments
  4. Intracept $626 7 payments
  5. General - Pain Management $389 8 payments
  6. ZTLido $347 19 payments
  7. WaveWriter Alpha Prime 16 $340 4 payments
  8. SPECTRA WAVEWRITER $292 2 payments
  9. Omnia $256 4 payments
  10. SPRINT PNS System $222 2 payments
  11. Other $2,634 88 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

828

Median for Interventional Pain Management: 1,220

Drug cost

$59,379

Median for Interventional Pain Management: $39,344

Branded share of claims

49.5%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ztlido Lidocaine Brand 17 $15,387
Xtampza Er Oxycodone Myristate Brand 15 $15,190
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 258 $8,404
Movantik Naloxegol Oxalate Brand 15 $7,589
Lidocaine Generic 19 $2,110
Fentanyl Generic 13 $2,070
Oxycodone Hcl Generic 73 $1,674
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 55 $1,447
Diclofenac Sodium Generic 32 $1,355
Gabapentin Generic 84 $802

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 2 billing codes

Paid by Medicare

$6,561

Medicare's payments for the services billed

Medicare patients

63

Average age 69

Services billed

73

30 women, 33 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 43%
Ischemic heart disease 38%
Diabetes 37%
Chronic kidney disease 29%
COPD 25%
Heart failure 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

125 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record